Directorate Change
London, UK - 02 July 2018: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE:OXB), a leading gene and cell therapy group, today announces, as previously stated on 4 June 2018, Peter Nolan has retired from his role as Chief Business Officer and has stepped down from the Board.
- Ends -
For further information, please contact:
|
|
Oxford BioMedica plc: Tel: +44 (0)1865 783 000
John Dawson, Chief Executive Officer
Stuart Paynter, Chief Financial Officer
Financial PR Enquiries: Tel: +44 (0)20 3709 5700
Consilium Strategic Communications
Mary-Jane Elliott / Matthew Neal /
Oliver Manser / Laura Thornton
Peel Hunt (Joint Corporate Broker): Tel: +44 (0)20 7418 8900
James Steel / Dr. Christopher Golden
WG Partners (Joint Corporate Broker): Tel: +44 (0)20 3705 9321
David Wilson / Claes Spång
Notes for editors
About Oxford BioMedica
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Bioverativ, Sanofi, Axovant, Orchard Therapeutics, GC LabCell and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 320 people. Further information is available at www.oxfordbiomedica.co.uk.